A potential treatment for brain injuries has shown encouraging data in a clinical trial, according to the company behind it.
Biopharmaceutical firm Moleac said data published in the journal Neuropharmacology shows that the medicine NeuroAID had positive effects on neuronal and brain injuries as well as in the recovery of neurological functions.
According to the company, the findings demonstrate that NeuroAID was involved in decreasing cognitive deficits, preventing death of threatened neuronal tissues, and improving functional outcomes by repairing and restoring neuronal circuits.
The treatment is also said to increase survival rate in rodent stroke models and has shown efficacy in reducing stroke severity when used as a preventative measure.
"These results pave the way for new indications of NeuroAiD beyond stroke recovery such as prevention, cognitive impairments and dementia. It is good news for patients who are in need of treatment in this under-served therapeutic area," said David Picard, chief executive officer of Moleac.
Moleac, which was set up in 2003, was named Singapore Entrepreneurial Company of the Year by Frost and Sullivan in 2009.
News brought to you by Serious Law, specialists in brain injury